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Human papillomavirus (HPV) is widely accepted as a causative agent of cervical cancer. The dis-
tribution and prevalence of HPV types depend on geographic region and demographic factors. The 
aim of this study was to investigate the relationship between the presence of various HPV types 
and the outcome of cytological examination. Cervical smears were obtained from 125 women from 
southern Poland: low grade squamous intraepithelial lesions (LSIL) — 44, high grade squamous 
intraepithelial lesions (HSIL) — 12, cervical carcinoma — 27 and 42 women without abnormal-
ity in cytology as a control group. DNA was extracted from the smears and broad-spectrum HPV 
DNA amplification and genotyping was performed with the SPF 10 primer set and reverse hybridi-
sation line probe assay (INNO-LiPA HPV Genotyping, Innogenetics). HPV DNA was detected in 
approximately 72% cases, more frequently in women with squamous intraepithelial lesions and 
cervical carcinoma than in the control group (P < 0.0005). The most frequent type found was HPV 
16 (37%), followed by HPV 51 (28%) and HPV 52 (17%). A single HPV type was detected in 51% 
positive cases, more frequently in cervical cancer specimens. Multiple HPV infection was dominant 
in women with LSIL and normal cytology. Prevalence of HPV 16 increased with the severity of 
cervical smear abnormality. For women HPV 16 positive, the relative risk (odds ratio) of the occur-
rence of HSIL and cervical cancer versus LSIL was 14.4 (95% CI, 3.0–69.2; P=0.001) and 49.4 (95% CI, 
6.5–372.8; P<0.001), respectively. Genotyping of HPV will allow better classification of women with 
cervical abnormalities into different risk groups and could be useful in therapy.
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INTRODUCTION
Human papillomavirus (HPV) has been im-
plicated with a high frequency in the aetiology and 
pathogenesis of dysplasia and carcinoma of the uter-
ine cervix. HPV is a small (52–55 nm), nonenveloped 
virus with a circular, double-stranded DNA. So far, 
more than 100 different HPV genotypes have been 
identified based on differences in DNA sequence. 
These HPV types can be classified according to vari-
ous criteria, e.g. their tissue tropism, oncogenic po-
tential and phylogenetic classification. More than 30 
types are commonly found in the genital tract. These 
include several HPV genotypes, such as HPV 16, 18, 
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82 that 
are known as high-risk HPV, capable of causing pro-
gression to cancer in the uterine cervix, and further 
three genotypes (HPV 26, 53, and 66) as probable 
high-risk types. In contrast, other genotypes, such as 
HPV 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, and 81 have 
been designated as low-risk HPV and rarely, if ever, 
lead to cancer (Remmink et al., 1995; zur Hausen H., 
2000; Bosch et al., 2002; Muňoz et al., 2003). Many 
HPV genotypes do not have an agreed-upon status. 
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Meyer et al. (2001) classified HPV 53 as low-risk, 
and Muňoz et al. (2003) found discrepancies between 
phylogenetic and epidemiologic evidence for types 
70 and 73.
Women infected with high-risk HPV types are 
considered to be at a higher risk for the development 
of cervical cancer than those who are not infected 
with HPV or are infected with low-risk HPV types 
(Remmink et al., 1995; Cuzik et al., 1995; Bosch et al., 
2002; Muňoz et al., 2003; Schmidt et al., 2005). Papil-
lomaviruses cannot be cultured, serological assays are 
useless, too. Diagnosis of HPV infection has thus to 
based on molecular methods, including liquid hybrid-
isation (e.g. Hybrid Capture), Southern and dot blot 
hybridisation, or PCR (Manos et al., 1989; Low et al., 
1990; Jacobs et al., 1997; Clavel et al., 1999; Gravitt et 
al., 2000; Finan et al., 2001). Various PCR-based meth-
ods have been described for the identification of HPV 
genotypes. Individual genotypes can be detected by 
type-specific PCR primer sets. However, these re-
quire the performance of multiple parallel assays for 
each sample, and type-specific PCR primers have not 
been reported for each HPV genotype. Alternatively, 
general PCR primer sets can be used, permitting si-
multaneous amplification of a broad range of HPV 
genotypes. The SPF-PCR system amplifies a 65 bp 
fragment of the L1 region which is highly conserved 
between HPV types (Kleter et al., 1998). Subsequently 
the amplified HPV DNA is genotyped using a reverse 
hybridisation line probe assay (Kleter et al., 1999). The 
present study was undertaken to determine the prev-
alence of HPV genotypes and assess the correlation 
of these findings with cytological diagnosis.
MATERIALS AND METHODS
One hundred and twenty-five cervical smears 
derived from women aged 20–75 (mean 39 ± 15) 
years were investigated. These samples were clas-
sified as follows: normal cytology — control group 
(n = 42), low grade squamous intraepithelial lesions 
— LSIL (n = 44), high grade squamous intraepithe-
lial lesions — HSIL (n = 12), and cervical carcinoma 
(n = 27), confirmed by histopathological examination 
using FIGO IIa/IIb stages according to the Interna-
tional Federation of Gynecology and Obstetrics. All 
cervical smears were obtained before the biopsy and 
were taken with a cervical brush and collected to 5 
ml of phosphate-buffered saline, pH 7.2, and stored 
frozen at –70oC until tested. 
DNA isolation. DNA was isolated using Ge-
nomic DNA Prep Plus kit (A&A Biotechnology, 
Gdańsk, Poland). Cell samples were lysed in a buffer 
with Proteinase K (1.25 mg/ml) and chaotropic salts. 
Addition of ethanol caused DNA to bind when the 
lysate was spun through a silica membrane in a micro-
centrifuge tube. Following washing to remove contam-
inants, DNA was eluted in 10 mM Tris/HCl, pH 8.5 
(preheated to 75°C). The final concentration of DNA 
was on average 80 ng/µl. The samples were stored at 
+4°C according to manufacturer’s instruction.
HPV DNA amplification. Broad-spectrum 
HPV DNA amplification was performed using a 
short PCR fragment (SPF10) primer set (Innogenet-
ics Inc, Gent, Belgium). The SPF10 primers, labelled 
with biotin at the 5’ end, amplified a 65 bp fragment 
from the L1 region of the HPV genome (Kleter et al., 
1998). 
The reaction was performed as described pre-
viously (Szostek et al., 2006). The final reaction vol-
ume was 50 µl and contained 10 µl of the isolated 
DNA, 10 mM Tris/HCl, pH 9.0, 50 mM KCl, 2.0 mM 
MgCl2, 0.1% Triton X-100, 0.01% gelatine, 200 µM of 
each deoxynucleoside triphosphates, 15 pmol of for-
ward and reverse primers each, and 1.5 U of Am-
pli Taq Gold DNA polymerase (Applied Biosystems, 
Foster City, Ca, USA). The PCR conditions were as 
follows: polymerase activation 9 min at 94°C, 40 cy-
cles of 30 s at 94°C, 45 s at 52°C, 45 s at 72°C and a 
final extension of 5 min at 72°C.
Each experiment was performed with sepa-
rate positive (DNA from CaSki and HeLa cells) and 
negative (H2O) PCR controls. 
Analysis of the PCR products was performed 
by electrophoresis in 3% agarose gel.
β-Actin PCR analysis was performed to con-
firm the presence of human DNA in all specimens, 
according to Guzik and co-workers (1999).
HPV genotyping. Typing of the SPF10 am-
plimers was performed with reverse hybridisation 
using the INNO-LiPA HPV genotyping assay (Inno-
genetics, Gent, Belgium) which permits specific de-
tection of 25 HPV genotypes (Kleter et al., 1999): 
— high-risk HPV genotypes 16, 18, 31, 33, 35, 39, 45, 
51, 52, 56, 58, 59, 66, 68, 70;
— low-risk HPV genotypes 6, 11, 34, 40, 42, 43, 44, 
53, 54, 74.
Statistics. The frequency of infection in cervi-
cal smear abnormality groups were compared us-
ing Fisher exact test. The Kruskal-Wallis test was 
used to compare age in studied groups. The relative 
risk (odds ratio) of LSIL, HSIL and cervical cancer 
through HPV infection was adjusted to age and as-
sessed using multivariate logistic regression. The 
analyses were carried out using the STATA 8.0 soft-
ware package. 
RESULTS
HPV DNA was found in 72% of the samples, 
more frequently in women with HSIL — 91.7% (95% 
CI: 61.5–99.8) and LSIL — 97.7% (95% CI: 88.0–99.9) 
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than in women with normal cytology — 21.4% (95% 
CI: 10.3–36.8) (P < 0.005). The all specimens from 
women with cervical cancer were HPV-positive. 
Nineteen different HPV genotypes were detected by 
reverse hybridisation in this study (Table 1). Among 
the HPV-positive samples, the most frequent type 
was HPV 16 (36.7%), followed by HPV 51 (27.8%) 
and HPV 52 (16.7%). The incidence rates of HPV 18 
infection were lower than those for HPV 16, 51, and 
52. For nine cervical scrapes the HPV type could not 
be determined. 
The occurrence of HPV 16 seems to increase 
with the severity of cervical smear abnormality 
(Fig. 1). It was not detected in the control group, 
and its proportion increased from 9.1% (95% CI: 
2.5–21.7) in the LSIL group and 58.3% (95% CI: 27.7–
84.8) in the HSIL group to 81.5% (95% CI: 61.9–93.7) 
in samples of cervical carcinoma. The prevalence of 
other HPV types was more frequent in women with 
LSIL (77%) than in HSIL (50%) and cervical cancer 
(33%) groups. These differences were statistically 
significant (P < 0.001). 
A single HPV type was detected in 51% of 
the positive cases (Table 2). Double infections dom-
inated among the multiple ones. In women with a 
single HPV type, HPV 16 constituted 52% while in 
mixed infections type 51 was twice as frequent as 
HPV 16, 22% and 11%, respectively. A statistically 
significant difference was found in the numbers of 
detected virus types among patients with different 
cytological diagnoses (P < 0.0001). In women with 
normal cytology or LSIL, mixed-types of HPV were 
significantly more frequent than in the group of 
women with advanced dysplastic process and cer-
vical cancer, 48% and 26%, respectively (P < 0.05). 
The relative risk of cervical carcinoma assessment 
by HPV type showed that HPV 16-positive cases 
had a 30-fold higher risk of cervical carcinoma 
(95% CI: 6.3–143.1; P < 0.001). For women with HPV 
16 infection, the relative risk (odds ratio) of the oc-
currence of HSIL and cervical cancer versus LSIL 
was, respectively, 14.4 (95% CI, 3.0–69.2; P = 0.001), 
and 49.4 (95% CI, 6.5–372.8; P < 0.001). All odds ra-
Table 1. HPV types in cervical smears
Cytological 
classification
 
HPV+ (%)
HPV types
un
id
en
tifi
ed
n
 6 11 16 18 31 33 35 39 42 44 45 51 52 53 56 58 66 68 74
Ca* 27 27 (100)  2 22 3       1 4 2    3 1  1
HSIL 12 11 (92)   7 2 1     1  3         
LSIL 44 43 (98) 3 2 4 5 5 3 1 1 4   13 11 3 2 3 3  1 7
Normal 42 9 (21)** 1 1         1 5 2 1 1  1   1
Total 125 90 (72) 4 5 33 10 6 3 1 1 4 1 2 25 15 4 3 3 7 1 1 9
*squamous cell carcinoma; ** P < 0.005
0
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HPV 16             other HPV types 
Figure 1. Frequency of HPV 16 and others HPV types in 
women with different cytological diagnoses
Table 2. Single and multiple HPV types among 90 infected women 
Cytological
classification Number
Number of HPV-positive women (%)
single double triple more than triple unidentified type
LSIL 43 15 (35) 16 (37) 3 (7) 2 (5) 7 (16)
HSIL 11 8 (73) 3 (27) 0 0 0
Ca* 27 19 (70) 3 (11) 3 (11) 1 (4) 1 (4) 
Normal cytology 9 4 (44) 3 (33) 1 (9) 0 1 (9)
Total 90 46 (51) 25 (28) 7 (8) 3(3) 9 (10)
*squamous cell carcinoma
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tios were adjusted to age using logistic regression 
analysis.
DISCUSSION
In countries that have screening programs for 
cervical cancer using cervical cytology significant re-
ductions have been achieved in both the incidence 
and mortality from cervical cancer. In Poland, cervi-
cal cancer is the fourth most common neoplasm in 
women. There are 3439 new cases recorded annual-
ly, of which 53% of the patients die (Wojciechowska 
et al., 2005). HPV infections are associated with an 
increased risk for the development of cervical carci-
noma. Therefore accurate detection of HPV infection 
is clinically important and requires reliable diagnos-
tic tools. 
It is known that only 1% of LSIL and about 
12% of HSIL progress to invasive cervical cancer. 
Therefore, identification of high-risk HPV types in 
cervical scrapes would help to identify patients with 
an increased risk for development of cervical cancer. 
In our study the HPV prevalence was 98% in LSIL, 
92% in HSIL and 100% in invasive cervical carcino-
ma. These data were closer to the results obtained 
for North America rather than for European coun-
tries (Clifford et al., 2003a; 2003b; 2005).
However, only 21% of women with nor-
mal cytology were found to have HPV infection, 
which was similar to data from southeastern Hun-
gary (23%) obtained from comparable study groups 
(Nyari et al., 2004) and higher than data from the 
Czech Republic (5.3%) (Tachezy et al., 2003) and oth-
er Poland regions (Michalski et al., 2004; Bardin et 
al., 2008), but lower than the results from the Neth-
erlands (38%) (Melchers et al., 1999). Studies of Per-
rons et al. (2002) showed that the prevalence of HPV 
in women without atypical changes in cervical epi-
thelial cells, estimated with PCR using two different 
pairs of primers, was 22% for MY09/11 and 72% for 
SPF10 (Perrons et al., 2002). On the other hand, the 
frequencies of HPV infection in cytologically nega-
tive Italian women over 30 years of age were about 
10% by Hybrid Capture assay and PCR, however, 
colposcopy revealed minor abnormalities for the ma-
jority of those women (De Francesco et al., 2005).
Studies carried out in other regions of Po-
land (Dudkiewicz et al., 2001; Liss et al., 2002; Dy-
bikowska et al., 2002; Bardin et al., 2002) showed a 
lower rate of HPV infection in women with the di-
agnosis of LSIL (48%) and HSIL (62%) and cervical 
carcinoma (75%, 70%, 53%, 73.9%). These differences 
are probably a result of the variability of the tech-
niques used for identification of the virus in those 
studies. The results of our studies confirm the data 
of other authors (Melchers et al., 1999; Perrons et al., 
2002; Cho et al., 2003) that there is a direct depend-
ence between the degree of advancement of changes 
within the uterine cervix and the presence of HPV 
infection, especially of the high-risk types. This rela-
tionship is best visible for HPV 16. In our material, 
the presence of this virus, in single as well as mixed 
infections, was noted in 81% of women with cervical 
carcinoma, 64% with HSIL and 9% with LSIL.
We have used SPF-10 HPV primers which had 
been shown to offer higher sensitivity than is avail-
able with other PCR methods using general primer 
sets (Kleter et al., 1998; Perrons et al., 2002). Also, 
the reverse hybridisation using multiple probes on 
line permitted simultaneous detection of 25 different 
HPV types. Whereas Kleter et al. (1999) and Quint 
et al. (2001) observed that the prevalence of multi-
ple genotypes increased with the severity of cervical 
lesions and was higher in the cervical smears than 
in the biopsy, in the present study multiple HPV 
infection was more common in smears diagnosed 
as LSIL and normal. On the other hand, those au-
thors agree with the fact that single types of viruses, 
mainly HPV 16, are present in cervical cancer. In our 
study, the prevailing HPV types in cervical neoplas-
tic lesions were HPV 16 (36%), HPV 51 (28%) and 
HPV 52 (17%). Despite differences in the frequency 
of occurrence of each of the high-risk types, depend-
ing on the geographical region and the study meth-
ods used, the dominance of HPV 16 was noted in 
most studies (Naucler et al., 2004; Silins et al., 2004; 
Ronco et al., 2005). Similarly to De Francesco et al. 
(2005), we showed a lesser role of HPV 18 in squa-
mous cervical cancer, which could be significant in 
studies relating to the composition of vaccines being 
prepared and their efficacy. The current vaccination 
strategy is based mainly on virus-like particles L1 
HPV 16 and L1 HPV 18 as immunogenes (Koutsky 
et al., 2002; Harper et al., 2004; Frazer, 2004). In cervi-
cal cancer prophylaxis it would be usefull to include 
a higher number of high-risk HPV types in the vac-
cines. Genotyping contributes to the knowledge of 
the prevalence of HPV types playing a role in in-
fections, which should then have an implication on 
the design of vaccines. Implementation of cervical 
cancer prophylaxis by HPV testing will allow better 
classification of patients into different risk groups 
and simplify the identification of patients at risk for 
developing this neoplastic disorder. The demonstra-
tion of persistent HPV infection, via multiple patient 
examinations and identification of the virus type, 
could be helpful in drawing therapeutical decisions.
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